液体五联疫苗在6-8周龄婴儿中的免疫原性与安全性III期非劣效研究
印度开展III期随机单盲非劣效研究,405名6-8周龄健康婴儿按2:1随机接种三剂研究性液体五联疫苗(DTwP-Hb-Hib)或Pentavac SD®对照疫苗,间隔4-6周。结果显示研究疫苗的血清转化率、血清保护率和几何平均滴度与对照疫苗相当且非劣效,两组均免疫原性良好且耐受性良好,未报告疫苗相关严重不良事件。
要点
- 研究性液体五联疫苗在6-8周龄婴儿中免疫原性非劣效于Pentavac SD®对照疫苗。
- 两组最常见局部不良事件为注射部位疼痛、红斑和肿胀,最常见全身不良事件为发热、易激惹和异常哭闹。
- 未报告疫苗相关严重不良事件,两种疫苗均免疫原性良好且耐受性良好。
核心结论
- 研究性液体五联疫苗(DTwP-Hb-Hib)在6-8周龄婴儿中免疫原性和安全性与Pentavac SD®疫苗非劣效。
研究设计与样本
- III期随机单盲非劣效研究,在印度开展,共纳入405名6-8周龄健康婴儿,按2:1随机分配接种三剂研究疫苗或对照疫苗,间隔4-6周。
主要发现
- 405名入组受试者中387名完成研究。
- 研究疫苗组在第三剂接种后4-6周的血清转化率、血清保护率和几何平均滴度与对照疫苗组相当且非劣效。
- 两组最常见局部不良事件为注射部位疼痛、红斑和肿胀,最常见全身不良事件为发热、易激惹和异常哭闹。
- 未报告疫苗相关严重不良事件。
临床怎么用
- 该研究为液体五联疫苗在6-8周龄婴儿中的免疫原性和安全性提供了III期随机对照证据,支持其与对照疫苗的非劣效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A liquid Pentavalent (DTwP-Hb-Hib) combination vaccine, developed by Human Biologicals Institute, underwent a Phase III clinical study in India. In this randomized, single blind, non-inferiority study, the immunogenicity and safety of this Investigational vaccine was compared with Pentavac SD® vaccine in 6-8 weeks old healthy infants. METHODS: A total of 405 healthy infants aged 6-8 weeks old were randomized in 2:1 ratio to receive three doses of either the Investigational liquid Pentavalent (DTwP-Hb-Hib) combination vaccine or Pentavac SD® vaccine at four to six weeks interval. Immunogenicity was compared by estimation of antibody titers before the first dose and 4-6 weeks after the third dose of vaccination. Safety of each vaccine was assessed and compared by collection of data on solicited and unsolicited adverse events throughout the study period. RESULTS: Out of a total of 405 enrolled subjects, 387 subjects completed the study. The seroconversion rates, seroprotection rates and geometric mean titres of the Investigational liquid Pentavalent (DTwP-Hb-Hib) combination vaccine group were found to be comparable and non-inferior to the Pentavac SD® vaccine group at 4-6 weeks after the third dose of vaccination. Pain, erythema and swelling at the site of injection were found to be the most common local adverse events whereas fever, irritability and unusual crying were found to be the most common systemic adverse events in both the vaccine groups. No vaccine related serious adverse event was reported. In this study, both the Investigational vaccine as well as the Comparator vaccine were found to be immunogenic and well tolerated. CONCLUSION: After assessment of the results of the study it was concluded that the Investigational liquid Pentavalent (DTwP-Hb-Hib) combination vaccine developed by Human Biologicals Institute was immunogenic and safe when administered to infants aged 6-8 weeks and was non-inferior in immunogenicity and safety to Pentavac SD® vaccine. Clinical Trial Registry of India Identifier: CTRI/2016/01/006541.
引用
- Susarla SK, Gupta M, Mantan M, et al. Immunogenicity and safety of a liquid Pentavalent (DTwP-Hb-Hib) combination vaccine manufactured by Human Biologicals Institute in 6-8 weeks old healthy infants: A phase III, randomized, single blind, non-inferiority study. Vaccine. 2019. PMID: 31331773. doi:10.1016/j.vaccine.2019.06.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。